{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Unevaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Complete response + Partial response using RECIST 1.1 (Response Evaluation Criteria in Solid Tumor)","groups":[{"description":"Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Bevacizumab 7.5 mg/kg IV over 90 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.","id":"OG000","title":"Bevacizumab + Capecitabine + Oxaliplatin"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"39 months","title":"To Determine the Response Rate (RR) for CAPOX and Bevacizumab","type":"SECONDARY","unitOfMeasure":"Participants"}